Literature DB >> 11388653

Parkinson's disease and other alpha-synucleinopathies.

M Goedert1.   

Abstract

Parkinson's disease is the most common movement disorder and the second most common neurodegenerative disease. Neuropathologically, it is characterized by the degeneration of nerve cells that develop filamentous inclusions in the form of Lewy bodies and Lewy neurites. Recent work has shown that rare, familial forms of Parkinson's disease are caused by missense mutations in the alpha-synuclein gene and that the filamentous lesions of Parkinson's disease are made of alpha-synuclein. The same is true of the Lewy body pathology that is associated with other neurodegenerative diseases, such as dementia with Lewy bodies. The filamentous inclusions of multiple system atrophy have also been found to be made of alpha-synuclein, thus providing an unexpected molecular link with Lewy body diseases. Recombinant alpha-synuclein assembles into filaments with similar morphologies to those found in the human diseases and with a cross-beta diffraction pattern characteristic of amyloid. The related proteins beta-synuclein and gamma-synuclein are poor at assembling into filaments. They are not present in the pathological filamentous lesions and have not been found to be linked to genetic disease. The new work has established the alpha-synucleinopathies as a major class of neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388653     DOI: 10.1515/CCLM.2001.047

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  33 in total

1.  Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro.

Authors:  John Goers; Vladimir N Uversky; Anthony L Fink
Journal:  Protein Sci       Date:  2003-04       Impact factor: 6.725

Review 2.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

Review 3.  [Postmortal diagnosis of Parkinson's disease].

Authors:  D Sandmann-Keil; H Braak
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

Review 4.  Amyloidogenesis of natively unfolded proteins.

Authors:  Vladimir N Uversky
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

Review 5.  Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration.

Authors:  Blanca A Silva; Leonid Breydo; Vladimir N Uversky
Journal:  Mol Neurobiol       Date:  2012-09-01       Impact factor: 5.590

Review 6.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

7.  Modulation of alpha-synuclein aggregation by dopamine analogs.

Authors:  Diane Latawiec; Fernando Herrera; Alpan Bek; Valeria Losasso; Michela Candotti; Federico Benetti; Elvio Carlino; Agata Kranjc; Marco Lazzarino; Stefano Gustincich; Paolo Carloni; Giuseppe Legname
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

8.  Protein disorder in the human diseasome: unfoldomics of human genetic diseases.

Authors:  Uros Midic; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

9.  Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics.

Authors:  Olivia Wise-Scira; Ahmet Kemal Aloglu; Aquila Dunn; Isin Tuna Sakallioglu; Orkid Coskuner
Journal:  ACS Chem Neurosci       Date:  2013-01-30       Impact factor: 4.418

10.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Authors:  Valerie Cullen; Maria Lindfors; Juliana Ng; Anders Paetau; Erika Swinton; Piotr Kolodziej; Heather Boston; Paul Saftig; John Woulfe; Mel B Feany; Liisa Myllykangas; Michael G Schlossmacher; Jaana Tyynelä
Journal:  Mol Brain       Date:  2009-02-09       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.